N/A
N=8
Characterizing Methamphetamine Withdrawal in Recently Abstinent Methamphetamine Users: A Pilot Study
Methamphetamine Dependence · Methamphetamine Withdrawal
Bottom Line
View on ClinicalTrials.gov: NCT00653263 ↗Enrolled (actual)
8
Serious AEs
0.0%
Results posted
Mar 2010
Primary outcome: Primary: Methamphetamine Selective Severity Assessment (MSSA) — 48.2 "units on a scale" — p=<0.05
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Arkansas
- Primary completion
- Aug 2008
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Methamphetamine Selective Severity Assessment (MSSA) |
48.2 | <0.05 sig |
| PRIMARY Methamphetamine Withdrawal Assessment (MAWA) |
20.3 | <0.05 sig |
| SECONDARY Hamilton Depression Rating Scale (HAM-D) Rating Score |
18.5 | <0.05 sig |
Summary
Methamphetamine use has escalated in recent years. Methamphetamine use has also spread throughout the country. Although much information has been gathered on the treatment of cocaine abuse, very little information has been obtained on the treatment of methamphetamine abuse. One of the first steps in developing appropriate treatment is to examine the effects of stopping a particular substance's use on individuals abusing that substance. To date this has not been well studied for people abusing methamphetamine. The purpose of this study is to better understand and develop accurate ways of measuring symptoms associated with stopping the use of methamphetamine in people that are abusing methamphetamine. If the withdrawal symptoms are able to be effectively measured, this will help to develop treatments targeted at alleviating these symptoms. These symptoms are often associated with relapse to use of that substance.
Eligibility Criteria
Inclusion Criteria
- 18-65 years old
- Subjects must have a history of methamphetamine use, with recent use verified by a urine toxicology screen positive for amphetamines
Exclusion Criteria
- Current diagnosis of drug or alcohol physical dependence (other than methamphetamine or tobacco)
- Schizophrenia, or bipolar type I disorder
- Present or recent use of over-the-counter or prescription psychoactive drug or drug(s) that may affect mood ratings
- Current suicidality or psychosis
- Pregnancy: hormonal changes during pregnancy can affect mood which might produce a potential confound if pregnant women were enrolled
Data sourced from ClinicalTrials.gov (NCT00653263). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.